Selected Publications

E. P. Taranto , W. Fawn , C. Desirae , E. Walinsky , S. Deluca , L. Bayne, E. P. Wileyto, A. Shirali, C. J. Robbins, Y. Abdou,J. Anampa, M. Balic, J. V. Canzoniero, N. C. Chen, F. Howard, L. Huppert, A. Kahn, C. Mainor, J. Mouabbi, V. Nair, T.Degeer, J. Weidler, T. McNicholas, C. Serway, J. Reischl, M. Bates, R. Monroe, D. L. Rimm, A. DeMichele: Quantifyher (trial in progress): quantitative immunofluorescence and/or messenger rna to measure her2 expression in patients with metastatic breast cancer treated with trastuzumab deruxtecan (tbcrc066). Clin Cancer Res 32(4_Supplement): PS4-03-12, Feb 2026 Notes: Poster Session Abstracts, San Antonio Breast Cancer Symposium, December 2025.

A. DeMichele, L. Bayne, E. Walinsky, L. Berry, S. Deluca, C. G. Smith, A. Chevalier, B. Ambasager, P. Sanchez, J. Heaven, E. Chislock, T. Pan, J. Graves, G. Belka, J. Wang, E. Taranto, A. Nayak, M. Feldman, A. Clark, L. Chodosh: 5-year outcomes and ctdna findings in the clever trial targeting disseminated dormant tumor cells Clin Cancer Res 32(4_Supplement): PD5-02, Feb 2026 Notes: Poster Session Abstracts, San Antonio Breast Cancer Symposium, December 2025.

Taranto E, DeMichele A: Evaluating the clinical utility of ctDNA testing to identify molecular cancer progression – lessons from SERENA-6. NPJ Breast Cancer 12(1): 18, Jan 2026.

Taranto E, Seewald NJ, Bayne LJ, Deluca S, Shih NC, Sanchez P, Nivar I, Ambasager B, Murray C, Chevalier A, Smith CG, Makhlin I, Rohn K, Goodspeed BL, Savage J, Wileyto P, Wang J, Belka G, Chislock E, Berry LR, Berry D, Nayak A, Feldman M, Clark AS, Chodosh LA, & DeMichele A.: Circulating tumor DNA (ctDNA), dormant disseminated tumor cells (DTCs) and recurrence outcomes in breast cancer survivors on the SURMOUNT Study. Clin Cancer Res 31 (12_Supplement): PS9-03, Jun 2025 Notes: Poster Session Abstracts, San Antonio Breast Cancer Symposium, December 2024.

Taranto E, Barta S, Bhansali R.: Central Nervous System Relapse in T and NK Cell Lymphomas. Curr Hematol Malig Rep 18(6): 243-251. Dec 2023.

Taranto E, Hwang WT, Alfaro M, Surapaneni AS, Gill SK, Feldman T, Randall MP, Spinner MA, Furqan F, Shah NN, Samara Y, Mei MG, Herrera AF, Moskowitz A, Shah GL, & Svoboda J.: Engraftment Syndrome during Autologous Stem Cell Transplant in Hodgkin Lymphoma Patients Treated with Checkpoint Inhibitors: A Multicenter Retrospective analysis. Blood 142(Supplement 1): 3603, Nov 2023 Notes: "Poster Presentation" ASH Annual Meeting, San Diego, CA.

Merryman R, Redd R, Taranto E, Ahmed G, Jeter E, McHugh K, Brown J, Crombie J, Davids M, Fisher D, Freedman A, Jacobsen E, Jacobson C, Kim A, LaCasce A, Lampson B, Ng S, Odejide O, Dahi P, Nieto Y, Joyce R, Chen Y, Herrera A, Armand P.: Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv 7(17): 4748-4759. Sep 2023.

Merryman R, Spilberg G, Mondello P, Redd R, Taranto E, Ahmed G, Jeter E, Chase M, Salles G, Zelenetz A, Brown J, Crombie J, Davids M, Fisher D, Freedman A, Jacobsen E, Jacobson C, Kim A, LaCasce A, Lampson B, Ng S, Odejide O, Armand P, Jacene H. : Interim Positron Emission Tomography during Frontline Chemoimmunotherapy for Follicular Lymphoma. Hemasphere 7(2): e826. Jan 2023.

Taranto E, Redd R, Jeter E, McHugh K, Crombie JL, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, Odejide OO, Dahi PB, Nieto Y, Joyce RM, Chen YB, Bonjoc KC, Chaudhry A, Herrera AF, Armand P, Merryman RW.: Prognostic Value of Minimal Residual Disease among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation. Leuk Lymphoma 63(12): 2912-2917. Dec 2022.

Kline J, Heusinkveld L, Taranto E, Martin C, Tomasi A, Hsu I, Cho K, Khillan J, Murphy P & Pontejo S.: Structural and functional analysis of Ccr1l1, a Rodentia-restricted eosinophil-selective chemokine receptor homologue. J Biol Chem 296: 100373. Jan-Jun 2021.